Over my 11 years in practice, I have watched glaucoma management evolve significantly.
MIGS procedures have given us safer alternatives to traditional filtering surgery, but a gap has persisted. What do we offer patients who need more pressure reduction than angle-based MIGS provides but who are not ideal candidates for filtering surgery?
The reemergence of uveoscleral outflow enhancement, now supported by bio-interventional technology such as AlloFlo Uveo (Iantrek), presents a meaningful solution. By accessing the uveoscleral pathway via cyclodialysis that is reinforced with a homologous,